^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Thymic Carcinoma |
| Regimen: | CaT (carboplatin + paclitaxel) |
| Direction: | Sensitive |
Evidence:
Source:
Excerpt:
Thymic Carcinoma: Preferred (Other Recommended for Thymoma)...Paclitaxel and Carboplatin...Carboplatin/paclitaxel...Carboplatin AUC 6...Paclitaxel 200 mg/m2....Administered every 3 weeks...
